Belite Bio announced completion of the final subject visit in its two-year, Phase 3 DRAGON clinical trial evaluating Tinlarebant for Stargardt disease type 1, a degenerative retinal disorder with significant unmet medical need. The trial’s conclusion marks a critical milestone as the company advances its novel therapeutic towards regulatory submission and potential commercialization to address vision loss in affected patients worldwide.